NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its PGxHealth™ division, the provider of Therapeutic Diagnostics™, will present new data on the use of a replicated genetic marker in predicting the risk of clozapine-induced agranulocytosis (CIA) at the American Society of Hematology’s 48th Annual Meeting and Exposition (ASH) in Orlando, Florida. CIA is a rare but serious side effect of the schizophrenia treatment clozapine.
